Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Watson files for generic Mucinex D

This article was originally published in The Tan Sheet

Executive Summary

The Corona, Calif.-based firm seeks to market generic extended-release guaifenesin pseudoephedrine HCl 600 mg/60 mg and 1200 mg/120 mg, equivalent to Reckitt Benckiser's Mucinex D and Maximum Strength Mucinex D expectorant and nasal decongestant. Watson said June 10 it appears to be the first to file an abbreviated new drug application for the product, meaning it would be entitled to 180 days of generic market exclusivity should it overcome Reckitt's patents. Reckitt filed suit against Watson June 5, as it did upon Watson's April filings to market generic Mucinex and Mucinex DM (1"The Tan Sheet" April 27, 2009, p. 10). Watson says Mucinex D products totaled about $62 million in U.S. sales for the 12 months ended March 31, based on IMS Health data

You may also be interested in...



Watson Files ANDA For Mucinex DM, Gets In Line For Generic Guaifenesin

Watson Pharmaceuticals appears to be the first firm to file an abbreviated new drug application with FDA to market a private label version of Reckitt Benckiser's Mucinex DM

Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Biogen’s RoActemra Biosimilar Begins EU Approvals Process

The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel